S J Ryan Arends
YOU?
Author Swipe
View article: Retrospective analysis of antimicrobial resistance among Escherichia coli causing community-acquired urinary tract infections in the United States from 2010 to 2022
Retrospective analysis of antimicrobial resistance among Escherichia coli causing community-acquired urinary tract infections in the United States from 2010 to 2022 Open
These data highlight the need for more oral options when treating community-acquired UTIs.
View article: Antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> from United States medical centers (2019–2023)
Antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> from United States medical centers (2019–2023) Open
We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019–2023. Aztreonam-avibactam (MIC 50/90 , 2/4 µg/mL; 99.6% inhibited a…
View article: P-1060. <i>In vitro</i> Activity of Gepotidacin Tested Against Molecularly Characterized <i>Escherichia coli</i> Isolates Responsible for Urinary Tract Infections in the US (2019-2022)
P-1060. <i>In vitro</i> Activity of Gepotidacin Tested Against Molecularly Characterized <i>Escherichia coli</i> Isolates Responsible for Urinary Tract Infections in the US (2019-2022) Open
Background Gepotidacin (GEP) is a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial that inhibits bacterial DNA replication by a unique mechanism of action, distinct binding site and provides well-balanced inhibition (…
View article: P-1062. <i>In vitro</i> Activity of Gepotidacin and Comparator Agents against a Collection of <i>K. pneumoniae</i> Urine Isolates from the United States During 2019-2022
P-1062. <i>In vitro</i> Activity of Gepotidacin and Comparator Agents against a Collection of <i>K. pneumoniae</i> Urine Isolates from the United States During 2019-2022 Open
Background Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a unique mechanism of action, a distinct binding site and provides well-balanced inhibition (for mos…
View article: P-1083. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in United States Medical Centers (2019-2023)
P-1083. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in United States Medical Centers (2019-2023) Open
Background The occurrence of S. maltophilia infections has increased continuously in the last few years. We evaluated the in vitro activities of aztreonam-avibactam (ATM-AVI) and comparators against a large collection of S. maltophilia cli…
View article: P-1101. A Comparative Analysis of Resistance Rates Among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies
P-1101. A Comparative Analysis of Resistance Rates Among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies Open
Background Gepotidacin (GEP) is a novel oral antibacterial under development for the treatment of uncomplicated urinary tract infection (uUTI) and gonorrhea. This study reports drug resistance rates for large collections of Escherichia col…
View article: P-1528. <i>In Vitro</i> Activity of Omadacycline and Comparator Agents against a Collection of <i>Neisseria Gonorrhoeae</i> Urine Isolates Collected from the United States During 2018-2020
P-1528. <i>In Vitro</i> Activity of Omadacycline and Comparator Agents against a Collection of <i>Neisseria Gonorrhoeae</i> Urine Isolates Collected from the United States During 2018-2020 Open
Background Omadacycline (OMC) is a third-generation tetracycline (TET) class antibacterial approved for treatment of adults with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by indica…
View article: P-1080. Aztreonam-Avibactam Activity Against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023)
P-1080. Aztreonam-Avibactam Activity Against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023) Open
Background Aztreonam-avibactam (ATM-AVI) is under development to treat Gram-negative (GN) infections. We evaluated the antimicrobial susceptibility of GN bacilli causing pneumonia Activity of β-lactamase inhibitor combinations Methods 7,56…
View article: P-1059. <i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022)
P-1059. <i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022) Open
Background Gepotidacin (GEP) is a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial that inhibits bacterial DNA replication by a unique mechanism of action, distinct binding site, and provides well-balanced inhibition …
View article: P-1061. <i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022)
P-1061. <i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022) Open
Background Gepotidacin (GEP) is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a unique mechanism of action, distinct binding site and provides well-balanced inhibition (for…
View article: In Vitro Antimicrobial Activity of Taurolidine against Isolates Associated with Catheter-Related Bloodstream Infections
In Vitro Antimicrobial Activity of Taurolidine against Isolates Associated with Catheter-Related Bloodstream Infections Open
Background: Taurolidine exhibits broad antimicrobial activity and is a component of a recently FDA approved catheter lock solution (DefenCath®, taurolidine 13,500 μg/mL and heparin 1000 Units/mL) indicated for reducing the risk of catheter…
View article: <i>In vitro</i> activity of taurolidine against clinical <i>Candida auris</i> isolates: relevance to catheter-related bloodstream infections
<i>In vitro</i> activity of taurolidine against clinical <i>Candida auris</i> isolates: relevance to catheter-related bloodstream infections Open
Candida auris is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock solu…
View article: 2801. Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints
2801. Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints Open
Background In March 2023, the Clinical and Laboratory Standards Institute (CLSI) lowered the Enterobacterales susceptible (S)/resistant breakpoints for amikacin from ≤16/≥64 mg/L to ≤4/≥16 mg/L and gentamicin and tobramycin from ≤4/≥16 mg/…
View article: 2159. Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected in the United States in 2022
2159. Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected in the United States in 2022 Open
Background Gepotidacin is a novel, bactericidal, first-in-class triazaacenapthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and binding site and provides well-balanced inhibition of 2 different …
View article: Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020–2021)
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020–2021) Open
Ceftazidime-avibactam, ceftolozane-tazobactam and imipenem-relebactam were highly active, and exhibited similar coverage against a large contemporary collection of P. aeruginosa isolates from US hospitals. Cross-resistance among the newer …
View article: 641. Activity of Gepotidacin Tested Against Molecularly Characterized <i>Escherichia coli</i> Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)
641. Activity of Gepotidacin Tested Against Molecularly Characterized <i>Escherichia coli</i> Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020) Open
Background Gepotidacin is a novel first in class triazaacenaphthylene antibiotic in Phase 3 clinical trials for the treatment of gonorrhea and uncomplicated urinary tract infection (UTI). This study evaluates the epidemiology of E. coli (E…
View article: 1676. Activity of SPR206 and Comparator Agents Against <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> Causing Infections in United States Hospitals
1676. Activity of SPR206 and Comparator Agents Against <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> Causing Infections in United States Hospitals Open
Background SPR206 is a next generation polymyxin being developed to treat serious infections caused by Gram-negative (GN) multidrug-resistant (MDR) pathogens. The in vitro activity of SPR206 and comparators were monitored against GN pathog…
View article: 1675. Activity of Gepotidacin Against <i>Escherichia coli</i> Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States
1675. Activity of Gepotidacin Against <i>Escherichia coli</i> Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States Open
Background Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action that confers activity against most strains of target pathogens, such …
View article: 656. Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against <i>Pseudomonas aeruginosa</i> isolates from United States Medical Centers (2020-2021)
656. Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against <i>Pseudomonas aeruginosa</i> isolates from United States Medical Centers (2020-2021) Open
Background P. aeruginosa (PSA) is one of the most common Gram-negative organisms causing infections in hospitalized patients. Prompt administration of an effective antimicrobial is crucial for patients with systemic PSA infection. We evalu…
View article: 1684. Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of <i>Stenotrophomonas maltophilia</i> and <i>Burkholderia cepacia</i> Species Complex Causing Infections in United States (US) Medical Centers (2016-2021)
1684. Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of <i>Stenotrophomonas maltophilia</i> and <i>Burkholderia cepacia</i> Species Complex Causing Infections in United States (US) Medical Centers (2016-2021) Open
Background S. maltophilia has become a major cause of hospital-associated pneumonia. Aztreonam (ATM) is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs), including those intrinsically produced by S. maltophilia. Avibactam (…
View article: 1677. <i>In vitro</i> Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals
1677. <i>In vitro</i> Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals Open
Background SPR206 is a next generation polymyxin under clinical development to treat infections, such as pneumonia, bloodstream, and urinary tract infections caused by Gram-negative (GN) multidrug-resistant (MDR) pathogens. The in vitro ac…
View article: 1689. <i>In Vitro</i> Activity of Lefamulin Against Bacterial Pathogens Collected From Pneumonia Patients in United States and Latin America Medical Centers in 2020-2021
1689. <i>In Vitro</i> Activity of Lefamulin Against Bacterial Pathogens Collected From Pneumonia Patients in United States and Latin America Medical Centers in 2020-2021 Open
Background Lefamulin is a novel pleuromutilin protein synthesis inhibitor approved in the US, Canada, and Europe for the oral and intravenous treatment of community-acquired bacterial pneumonia (CABP) in adults due to typical and atypical …
View article: 1075. <i>In vitro</i> Activity of Gepotidacin against <i>Escherichia coli</i> Causing Urinary Tract Infections in the United States, Including Molecularly Characterized Fluoroquinolone Resistant Subsets
1075. <i>In vitro</i> Activity of Gepotidacin against <i>Escherichia coli</i> Causing Urinary Tract Infections in the United States, Including Molecularly Characterized Fluoroquinolone Resistant Subsets Open
Background Gepotidacin (GEP) is a novel bacterial type II topoisomerase inhibitor in Phase 3 clinical trials for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study characterized fluoroquinolone (FQ)-not…
View article: 1320. In Vitro Activity of Lefamulin against <i>Staphylococcus aureus</i> Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis
1320. In Vitro Activity of Lefamulin against <i>Staphylococcus aureus</i> Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis Open
Background Lefamulin is a first-in-class, oral and IV pleuromutilin antibiotic approved in the US, EU, and Canada for the treatment of community-acquired bacterial pneumonia (CABP) in adults. Lefamulin inhibits bacterial protein synthesis …
View article: 1041. <i>In vitro</i> activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections
1041. <i>In vitro</i> activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections Open
Background Tebipenem is under development as an oral treatment option for complicated urinary tract infections and acute pyelonephritis. This study further evaluated the in vitro activity of tebipenem against various fastidious organisms r…
View article: 1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected Worldwide between 2019-2020
1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected Worldwide between 2019-2020 Open
Background Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor under development for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study reports on the in v…
View article: 1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible <i>Streptococcus pneumoniae</i> from the United States (2008-2020)
1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible <i>Streptococcus pneumoniae</i> from the United States (2008-2020) Open
Background Ceftaroline (CPT) is a broad-spectrum cephalosporin with activity against S. pneumoniae (SPN), including multidrug-resistant (MDR) strains. CPT fosamil is approved for clinical use in the United States (US) to treat community-ac…
View article: 1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates
1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates Open
Background Tebipenem, an orally bioavailable carbapenem administered as a pro-drug, completed a phase 3 clinical trial for evaluating its safety and efficacy for the treatment of complicated urinary tract infection and acute pyelonephritis…
View article: 1036. <i>In Vitro</i> Analysis of AmpC β-lactamase Induction by Tebipenem in <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
1036. <i>In Vitro</i> Analysis of AmpC β-lactamase Induction by Tebipenem in <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> Open
Background Tebipenem (TBP) is an orally bioavailable carbapenem in clinical development in the US for treating complicated urinary tract infections and acute pyelonephritis. TBP possesses broad-spectrum activity against isolates producing …
View article: 1280. Minocycline Activity Against <i>Acinetobacter baumannii-calcoaceticus</i> Species Complex, Burkholderia Cepacia Complex, and <i>Stenotrophomonas maltophilia</i> from US Hospitals
1280. Minocycline Activity Against <i>Acinetobacter baumannii-calcoaceticus</i> Species Complex, Burkholderia Cepacia Complex, and <i>Stenotrophomonas maltophilia</i> from US Hospitals Open
Background Acinetobacter baumannii-calcoaceticus species complex (ACB), Burkholderia cepacia complex (BCC), and Stenotrophomonas maltophilia (SM) are opportunistic non-fermentative organisms that can cause serious hospital-acquired infecti…